郑翠侠, 韩兵, 周翔, 张荣新, 万欢英, 臧旺福, 陈中元. 非小细胞肺癌表皮生长因子受体P848L突变及其功能研究[J]. 蚌埠医学院学报, 2010, 35(8): 788-790,793.
    引用本文: 郑翠侠, 韩兵, 周翔, 张荣新, 万欢英, 臧旺福, 陈中元. 非小细胞肺癌表皮生长因子受体P848L突变及其功能研究[J]. 蚌埠医学院学报, 2010, 35(8): 788-790,793.
    ZHENG Cui-xia, HAN Bing, ZHOU Xiang, ZHANG Rong-xin, WAN Huan-ying, ZANG Wang-fu, CHEN Zhong-yuan. Epidermal growth factor receptor P848L mutation and its function in non-small-cell lung cancer[J]. Journal of Bengbu Medical College, 2010, 35(8): 788-790,793.
    Citation: ZHENG Cui-xia, HAN Bing, ZHOU Xiang, ZHANG Rong-xin, WAN Huan-ying, ZANG Wang-fu, CHEN Zhong-yuan. Epidermal growth factor receptor P848L mutation and its function in non-small-cell lung cancer[J]. Journal of Bengbu Medical College, 2010, 35(8): 788-790,793.

    非小细胞肺癌表皮生长因子受体P848L突变及其功能研究

    Epidermal growth factor receptor P848L mutation and its function in non-small-cell lung cancer

    • 摘要: 目的:检测一组中国非小细胞肺癌(non-small-cell lung cancer,NSCLC)患者的表皮生长因子受体(epidermal growth factor receptor,EGFR)突变情况,探讨检出的1例EGFR突变类型P848L的功能特征。方法:收集55例手术或活检确诊的NSCLC标本,抽提细胞DNA,对EGFR的1~27号外显子进行筛查以检出突变情况;利用EGFR野生型全长基因载体,通过定点诱变技术构建出P848L突变型,进一步构建出P848L突变与T790M突变的双重突变体,分别转入293T细胞,观察细胞EGFR磷酸化活性及EGFR靶向抑制剂吉非替尼对其磷酸化的抑制作用。结果:共发现8例NSCLC携带EGFR突变,均为腺癌患者,占非吸烟腺癌患者的34.78%(8/23);其中1例NSCLC患者携带P848L突变体的细胞对吉非替尼的抑制反应与野生型相近,低于经典型突变体;当引入T790M形成双重突变后,对吉非替尼的反应性显著下降。结论: EGFR激活突变在非吸烟的肺腺癌患者具有较高的发生率,而在鳞状细胞癌等类型未发现;P848L突变不能增强吉非替尼对EGFR受体酪氨酸磷酸化的抑制效应,在携带P848L突变的EGFR基因上,引进耐药的T790M突变,能完全抑制其对吉非替尼的敏感性。

       

      Abstract: Objective: To determine the mutation status of epidermal growth factor receptor (EGFR) in chinese non-small-cell lung cancer (NSCLC) patients,and after detected a rare mutant type of EGFR,P848L,to further study its functional feature.Methods: Fiftyfive NSCLC samples were enrolled in the study.The total DNA was extracted,then the 1-27 exons were sequenced for the detection of mutation.The P848L mutant EGFR construct and then the T790M mutation was generated by introducing a point mutation into the wildtype EGFR vector using a site-directed mutagenesis kit.Results: There were 8 cases of mutations being detected,all the mutationharboring patients were non-smoker with pathologic type of adenocarcinoma.In vitro study demonstrated that the P848L mutant had a similar response to gefitinib treatment,and P848L and T790M double mutant did respond to gefitinib.Conclusions: EGFR mutations occurred in only non-smoker patients with lung adenocarcinoma in this series.P848L mutant EGFR has a similar response as the widetype to gefitinib treatment,while double mutated with T790M diminished the response completely.

       

    /

    返回文章
    返回